Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-CD20 Antibody-PE (8W940) is a PE-conjugated Rabbit antibody targeting CD20. Anti-CD20 Antibody-PE (8W940) can be used in FCM.
Description | Anti-CD20 Antibody-PE (8W940) is a PE-conjugated Rabbit antibody targeting CD20. Anti-CD20 Antibody-PE (8W940) can be used in FCM. |
Ig Type | Monoclonal Rabbit IgG |
Clone | 8W940 |
Reactivity | Human |
Verified Activity | Profile of anti-CD20 reactivity on peripheral blood lymphocytes analyzed by flow cytometry. |
Application | FCM |
Recommended Dose | 2 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, Human CD20 Transfected CHO Cells and conjugated with PE under optimum conditions, the unreacted PE was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
Research Background | CD20 (membrane-spanning 4-domains, subfamily A, member 1), also known as MS4A1, is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed in all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections, and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells are usually in the normal range but can be very low.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | PE |
Others Formats | Unconjugated/APC/PerCP/FITC |
Antibody Types Available | 5 |
Immunogen | Human CD20 Transfected CHO Cells |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.